Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023)
Contineum Therapeutics (CTNM) posted quarterly Long-Term Debt Repayments of $3.1 million for Q2 2023, up 400.0% quarter-over-quarter from $625000.0 in Q1 2023.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023) Analysis & Trends
Contineum Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $3.1 million for Q2 2023.
- In Q2 2023, Long-Term Debt Repayments changed N/A year-over-year to $3.1 million; the TTM figure through Mar 2024 stood at $3.1 million (changed N/A YoY), while the FY2023 annual figure was $3.8 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q2 2023 stood at $3.1 million, up from $625000.0 in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $3.1 million in Q2 2023, with the low at $625000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Contineum Therapeutics | 628.34 Mn | 628.34 Mn | - | - |